How Moderna is Accelerating Innovation in Medicine
We have partnered with Invesco to discover how Moderna is reimagining the future of medicine with its mRNA technology platform.
Learn more about the innovative companies you can access by investing in Invesco QQQ ETF.
Moderna is the first true platform company in biology. All of our drugs use the same chemical components - the software of life. It's a bit like going from analog medicine, traditional old pharma, to digital medicine.
Messenger RNA is the information molecule in each of your cells that carries genetic instruction from your DNA into your cells to make protein like let's say insulin. It uses the four letters of life that codes everything in life.
Instead of having that mRNA come from your own genes, we're making it outside the body and then delivering it to yourselves, programming your cells to make proteins that your body needs to fight disease.
During the race against the COVID-19 virus, instead of spending years working in the labs on the vaccine, our team designed the vaccine in the computer in 48 hours.
We were able to take that existing technology and platform and plug in that particular sequence for the vaccine for COVID 19, and be able to hit the ground running with production.
What really played a big role was all the digital investment that was made from day one into the manufacturing facility, as well as technical development.
We have now entered the age of nucleic acid medicines. These are programmable medicines, which means that once you understand how to deliver the medicine, then you can just swap out the sequence of the nucleic acid to make an entirely new medicine.
Whether it be oncology, whether it be therapeutics for rare disease, there are so many unmet medical needs out there.
We're working on building a new blood vessel in people's hearts, in their own body, after a heart attack. We're working on autoimmune disease to rebalance your immune system so that if you have an autoimmune disease, you don't have it anymore.
Any investment that we make to a product is an investment to everything in our pipeline. That's the beauty of the mRNA platform and technology that we have.
The pace of medicine is going to be something like we have never seen in the industry. This is just the beginning. And I cannot wait to see where the next 5, 10, 20 years bring for helping more patients.
Invesco QQQ is not affiliated with Nasdaq